Cao Lihuan, Bu Rongfa, Oakley Jennifer I, Kalla Sara E, Blair Harry C
Department of Pathology, University of Pittsburgh School of Medicine, PA 15243, USA.
J Cell Biochem. 2003 May 1;89(1):152-64. doi: 10.1002/jcb.10486.
Estrogens have complex effects on the skeleton, including regulation of modeling and maintenance of bone mass, which vary with cell type and developmental stage. Osteoblasts are key regulators of skeletal matrix synthesis and degradation. However, whether osteocytes, osteoblasts or earlier progenitors mediate estrogen effects, and the importance of estrogen receptors (ERs) alpha and beta, remain unclear. To address estrogen response in human cells closely related to secretory osteoblasts, we studied MG63 cells with ERalpha or ERbeta reduced to low levels by stable transfection of antisense plasmids. Collagen and alkaline phosphatase expression increased with estrogen in wild-type and ERalpha-suppressed cells, but not in ERbeta-suppressed cells. Matrix secretion occurs as osteoblasts cease dividing, and, in keeping with this, cell proliferation was reduced by estrogen except in ERbeta-antisense cells. No effects of estrogen on wild type or ER-suppressed cells were seen in expression of BMP 2, the BMP antagonist noggin, or Indian hedgehog, products that regulate differentiation of osteoblasts. In contrast to expectations that estrogen would modulate bone degradation, RANKL, CSF-1, and osteoprotegerin did not respond measurably to estrogen, regardless of ER status. In keeping with this result, estrogen response was not observed in assays of osteoclast development from CD14 cells supported by wild-type or ER-silenced MG63 cells. Since estrogens are major regulators of bone degradation in vivo, estrogen effects on osteoclasts may depend on interaction with stimuli present in bone but absent in the model studied. cDNA hybridization showed that additional estrogen-binding proteins including ERRalpha and BCAR3 were expressed by MG63, but estrogen effects in ERbeta-silenced cells were small, so these proteins are either minor regulators in MG63 cells, or act in concert with stimuli in addition to estrogen. We conclude that, in the MG63 cell line, estrogen increases synthesis of matrix proteins via ERbeta, and that, in the absence of additional stimuli, these cells are not major mediators of estrogen effects on osteoclast differentiation. Further, ERalpha is probably much more important in earlier stages of skeletal development, such as growth plate response, than in osteoblasts.
雌激素对骨骼有复杂的影响,包括对骨建模的调节和骨量的维持,这些影响会因细胞类型和发育阶段而异。成骨细胞是骨骼基质合成和降解的关键调节因子。然而,骨细胞、成骨细胞或更早的祖细胞是否介导雌激素的作用,以及雌激素受体(ERs)α和β的重要性,仍不清楚。为了研究与分泌型成骨细胞密切相关的人类细胞中的雌激素反应,我们研究了通过稳定转染反义质粒使ERα或ERβ降低至低水平的MG63细胞。在野生型和ERα抑制的细胞中,胶原蛋白和碱性磷酸酶的表达随雌激素增加,但在ERβ抑制的细胞中则不然。基质分泌发生在成骨细胞停止分裂时,与此一致的是,除了ERβ反义细胞外,雌激素会降低细胞增殖。雌激素对野生型或ER抑制细胞中BMP 2、BMP拮抗剂头蛋白或印度刺猬因子(调节成骨细胞分化的产物)的表达没有影响。与雌激素会调节骨降解的预期相反,无论ER状态如何,RANKL、CSF-1和骨保护素对雌激素均无明显反应。与此结果一致,在由野生型或ER沉默的MG63细胞支持的CD14细胞破骨细胞发育试验中未观察到雌激素反应。由于雌激素是体内骨降解的主要调节因子,雌激素对破骨细胞的作用可能取决于与骨中存在但在所研究模型中不存在的刺激物的相互作用。cDNA杂交显示,MG63表达包括ERRα和BCAR3在内的其他雌激素结合蛋白,但雌激素对ERβ沉默细胞的影响很小,因此这些蛋白要么是MG63细胞中的次要调节因子,要么与雌激素以外的刺激物协同作用。我们得出结论,在MG63细胞系中,雌激素通过ERβ增加基质蛋白的合成,并且在没有其他刺激的情况下,这些细胞不是雌激素对破骨细胞分化作用的主要介导者。此外,ERα在骨骼发育的早期阶段(如生长板反应)可能比在成骨细胞中重要得多。